Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07214961 · ClinicalTrials.gov registry record · Phase 1

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase 1 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Prostate Cancer (CRPC), sponsored by ARTBIO.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
3
Study locations

NCT07214961 is a Phase 1 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Prostate Cancer (CRPC) that is actively recruiting participants, run by ARTBIO. The registered enrollment target is 80 participants, below the 223-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (64% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07214961, a Phase 1 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Prostate Cancer (CRPC), is actively recruiting participants, sponsored by ARTBIO.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
3
Study locations

Study Summary

This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced. The study includes dose escalation to identify a recommended dose and dose expansion to further assess safety and anti-tumour activity. Primary objectives are to characterize the safety profile and determine the optimal dose and schedule for future studies

Conditions Studied

Metastatic Castrate Resistant Prostate Cancer (mCRPC) Prostate Cancer (CRPC)

Interventions

  • DRUG AB001

Study Locations (3)

Michigan

  • BAMF Health - Grand Rapids

Nebraska

  • XCancer - Omaha

New Jersey

  • United Theranostics - Princeton

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-11-03
Est. Completion 2028-11-03
Phase Phase 1

Sponsor

ARTBIO

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07214961

The ClinicalTrials.gov registry entry for NCT07214961 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 223-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (64% lower). The listed sponsor is ARTBIO, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Castrate Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which AB001 is the first listed.

NCT07214961 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Nebraska, New Jersey.

Frequently Asked Questions

What is clinical trial NCT07214961 about?

NCT07214961 is a clinical study titled "Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)". This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced. The study includes dose esca...

What is the current status of trial NCT07214961?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-11-03. Estimated completion is 2028-11-03.

What conditions does trial NCT07214961 study?

This clinical trial studies the following conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (CRPC).

What interventions are being tested in trial NCT07214961?

The interventions under investigation include: AB001 (DRUG).

Who is sponsoring clinical trial NCT07214961?

This trial is sponsored by ARTBIO, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07214961 being conducted?

This trial has 3 study locations across Michigan, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

All registered trials for this condition

Prostate Cancer (CRPC)

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.